| Literature DB >> 26295242 |
Kirsten Benkendorff1, David Rudd2, Bijayalakshmi Devi Nongmaithem3, Lei Liu4, Fiona Young5,6, Vicki Edwards7,8, Cathy Avila9, Catherine A Abbott10,11.
Abstract
Marine molluscs from the family Muricidae hold great potential for development as a source of therapeutically useful compounds. Traditionally known for the production of the ancient dye Tyrian purple, these molluscs also form the basis of some rare traditional medicines that have been used for thousands of years. Whilst these traditional and alternative medicines have not been chemically analysed or tested for efficacy in controlled clinical trials, a significant amount of independent research has documented the biological activity of extracts and compounds from these snails. In particular, Muricidae produce a suite of brominated indoles with anti-inflammatory, anti-cancer and steroidogenic activity, as well as choline esters with muscle-relaxing and pain relieving properties. These compounds could explain some of the traditional uses in wound healing, stomach pain and menstrual problems. However, the principle source of bioactive compounds is from the hypobranchial gland, whilst the shell and operculum are the main source used in most traditional remedies. Thus further research is required to understand this discrepancy and to optimise a quality controlled natural medicine from Muricidae.Entities:
Keywords: choline esters; ethnomedicine; indoles; marine natural products; whelk
Mesh:
Substances:
Year: 2015 PMID: 26295242 PMCID: PMC4557022 DOI: 10.3390/md13085237
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Examples of Muricidae resources: Shell diversity (a) Chicoreus ramosus (Linnaeus, 1758); (b) Chicoreus virgineus (Röding, 1798); (c) Dicathais orbita (Gmelin, 1791); (d) Murex pecten (Lightfoot, 1786); Harvested Murex (e) on sale at a seafood market in Vietnam, and (f) processed for the seashell industry in India; Tyrian purple in the egg capsules of (g) D. orbita and (h) Phycothais reticulata (Quoy and Gaimard, 1833); (i) Operculum from D. orbita; (j) Tyrian purple; (k) indole, indirubin and isatin pigments; (l) Murex homeopathic remedy.
Figure 2Muricidae chemistry (a) showing the proposed formation of Tyrian purple from tryptophan in the hypobranchial glands; (b) indoxyl prochromogens; (c) choline esters; (d) bromoimidazoles and (e) bromoquinolines and quinoxoline.
Antimicrobial and antiviral activity of extracts and compounds isolated from Muricidae. Antibacterial activity tested against human pathogenic bacteria (Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa), aquatic pathogenic bacteria (Vibrio anguillarum, Vibrio harveyi, Vibrio alginolyticus, Enterococcus sericolicida) or marine biofilm bacteria (panel of 40 isolated strains); Antifungal activity against the yeast Candida albicans and antiviral activity against Herpes simplex virus HSV-1.
| Source species 1 | Source Tissue | Extract or Compound | Activity Profile |
|---|---|---|---|
| egg mass | CHCl3 | Inhibits Gram +ve and Gram -ve human and marine pathogenic bacteria and | |
| Diethyl ether | Inhibits Gram +ve and Gram -ve human pathogens at 10 mg/mL | ||
| EtOH | Inhibits Gram +ve and Gram -ve human pathogens at 0.1 mg/mL | ||
| Tyriverdin | Inhibits human Gram +ve and Gram -ve pathogens at 0.0005 mg/mL, active against | ||
| Tyrindoleninone | Inhibits human pathogens at 0.5–1 mg/mL, | ||
| 6 Bromoisatin | Inhibits Gram +ve and Gram -ve human pathogenic bacteria in the range of 0.1–1 mg/mL, but >1 mg/mL for
| ||
| egg mass | CHCl3 | Inhibits human pathogens at 10 mg/mL | |
| egg mass | CHCl3 | Inhibits human pathogens at 10 mg/mL | |
| egg mass | CHCl3 | Inhibits human pathogens at 1 mg/mL | |
| 2,4,5-Tribromo-1H-imidazole | Inhibits human pathogens at 0.1 mg/mL | ||
| whole body | MeOH | Inhibited 58% of the marine biofilm bacteria tested | |
| digestive gland | MeOH, H2O, DCM, Acetone | No activity against biofilm bacteria | |
| egg mass | MeOH | Inhibited 100% of the marine biofilm bacteria tested | |
| whole body | MeOH | Inhibited 50% of the marine biofilm bacteria tested | |
| digestive gland | H2O, DCM or Acetone | No activity against biofilm bacteria | |
| operculum | MeOH | Inhibited 50% of the marine biofilm bacteria tested | |
| egg mass | MeOH | Inhibited 50% of the marine biofilm bacteria tested | |
| whole body | MeOH/DCM | Inhibited 63% of the marine biofilm bacteria tested | |
| egg mass | MeOH | Inhibited 70% of the marine biofilm bacteria tested | |
| egg mass | CHCl3 | Inhibits human pathogens at 10 mg/mL | |
| egg mass | CHCl3 | Inhibits human pathogens at 10 mg/mL | |
| whole body | Acetone | Inhibited 60% of the marine biofilm bacteria tested | |
| whole body | Acetone | Inhibited 23% of the marine biofilm bacteria tested | |
| haemolymph | Proline rich peptides | Inhibited Gram +ve ( | |
| haemolymph | Haemocyanin | Inhibits the replication of Epstein-Barr virus at 1 μg/mL and Herpes simplex virus type 1 at 200 μg/mL | |
| whole body | MeOH | Inhibited 35% of the marine biofilm bacteria tested | |
| whole body | MeOH | Inhibited 25% of the marine biofilm bacteria tested | |
| whole body | MeOH | Inhibited 18% the marine biofilm bacteria tested | |
| egg mass | CHCl3 | Inhibits | |
| 2,4,5-Tribromo-1H-imidazole | Inhibits human pathogens at 0.1 mg/mL |
1 Accepted species names according to the World Register of Marine Species [88] with previously published genera in brackets.
Anti-cancer and steroidogenic properties of Muricidae extracts. Summary of the (a) in vitro assays and (b) in vivo animal models used to investigate the activity of Muricidae extracts and compounds.
| A range of female reproductive, colon and breast tumurs and lymphomas ( | MTS/MTT cell viability; Crystal violet; Caspase 3/7 activity for apoptosis; Lactate dehydrogenase for necrosis; Tunnel staining for apoptosis; Flow cytometry for apoptosis, necrosis and cell cycle analysis | |
| JAr and human granulosa cells | Radioimmunoassays (RIA); Steroidogenesis assays: estradiol (E2) and progesterone (P4) synthesis | |
| Recombinant or naturally purified protein kinases | CDK1/Cyclin B, CDK5/p25, GSK-3 and other protein receptor kinase assays | |
| Human leukemia HL-60 and human lung cancer A-549 | MTT cell viability and liquid-scintillation radioassay for cell proliferation (3H-TdR) | |
| Human leukemia HL-60 and human lung cancer A-549 | MTT cell viability and liquid-scintillation radioassay for cell proliferation (3H-TdR) | |
| SiHa-cervical squamous cell carcinoma, CaOV-ovarian adenocarcinoma, MIA PaCa-pancreatic carcinoma, RD 64-rhabdomyosarcoma, EJ-urinary bladder carcinoma and Lep-nontumor human lung cell line. | Cell proliferation assay and apoptosis indicated by DNA degradation and caspase-3 activation | |
| 647-V, T-24 and CAL_29 bladder cancer cells | MTT AND WST-1 cell viability assays, apoptosis with acridine orange/propidium iodine staining and gene expression profiles for 168 inflammatory cytokines and signal transduction pathways. | |
| Synthetic isatin derivatives [ | The human leukemic (U937, monocyte and Jurkat, T cell), breast (MDA-MB-231 and MCF-7), prostate (PC-3), and colorectal (HCT-116) | MTS cell viability, caspase 3/7 for apoptosis, CDK2 inhibition |
| Synthetic indirubin derivatives [ | Recombinant or naturally purified protein kinases | CDK1/Cyclin B, CDK5/p25, GSK-3 and other protein receptor kinase assays; affinity chromatography; crystallography and
|
| Synthetic indirubin derivatives [ | Human neuroblastoma and breast cancer cell lines | Apoptosis induction pathways |
| Synthetic indirubin derivatives [ | Human melanoma andmyeloid leukemia cell lines | Jak/Stat 3 phosphorylation, FLT3 inhibition |
| Synthetic isatin and indirubin derivatives [ | JAr and human granulosa cells for female hormones and H294 adrenal cells for male | RAI; ELISA for E2 and P4; E-screen (xeno-oestrogenic potential) for E2 receptor binding; H294 adrenal cells for cortisol, testosterone, androgen, and didehydroepiandrosterone |
| Synthetic indirubin derivatives [ | JAr and human granulosa cells | RAI |
| Colon cancer prevention | Apoptotic response to genotoxic damage by azoxymethane (AOM) in mice. Compounds delivered by oral gavage two weeks prior to AOM | |
| Bladder carcinoma treatment | MBT-2 heterotopic murine bladder carcinoma model | |
| Synthetic 6-bromoistain [ | Colon cancer prevention | Apoptotic response to genotoxic damage by AOM in mice. Compound delivered by oral gavage two weeks prior to AOM |
| Synthetic 6-bromoindirubin derivatives [ | Human melanoma treatment | Xenograph model in BALC/c mice, 14 day treatment |
| Synthetic indirubin derivatives [ | Renal, prostate, lung and colon cancer treatment | Xenograph model in BALC/c mice |
1 MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt), MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) and WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) are tetrazolium reduction assays for cell viability.
Figure 3The inhibitory concentration of Dicathais orbita crude extract and purified compounds required to reduce cell viability by 50% (IC50 mg/mL on a log scale) in a range of cell lines using tetrazolium salt (MTT or MTS) cell proliferation assays; female reproductive cancer cells JAr, OVCAR-3 and KGN, as well as primary derived (healthy) granulosa cells after 4 h exposure [69]; colon cancer HT29 and Caco-2 cells after 12 h exposure [68]; lymphoma U937 and freshly isolated human mononuclear cells after 4 h exposure [51,105]. For freshly isolated human mononuclear cells (MNC), the IC50 exceeded the maximum test concentration (1000 µg/mL) for the crude extract and semi-purified fractions after 4 h exposure [104], therefore results are presented for MNC viability after 60 min exposure using Trypan blue staining [126].
Effect of Muricidae extracts and synthetic analogue compounds on basal and gonadotrophin-stimulated progesterone and estrogen synthesis in vitro. Only the effects of non-cytotoxic concentrations of compounds are summarised in this table.
| Source | Compound | Cell Type | Hormone | Dose Response |
|---|---|---|---|---|
| Synthetic compounds 0, 0.00001, 0.0001, 0.001, 0.01, 0.1 mg/mL | 6,6′ dibromoindirubin | JAr | Basal P4 | N-shaped 1, low doses stimulated, 0 and high doses N/E, 4 h, 6 h, 8 h, 10 h |
| indirubin | Basal P4 | N-shaped, Low doses stimulated, 0 and high doses N/E, 24 h | ||
| 5-bromoisatin | Basal P4 | N-shaped, low doses stimulated, 0 and high doses N/E, 24 h | ||
| indirubin | GC | Basal P4 | U-shaped 2, 48 h, 72 h | |
| 5-bromoisatin | Basal P4 | Dose-dependent stimulation, 48 h | ||
| Hypobranchial gland extract 0, 0.005, 0.01, 0.05, 0.1, 0.5, 1 mg/mL | mixture of 6-bromoisatin, tyrindolinone, tyrindoleninone, tyrindoxyl sulphate | GC | Basal P4 | N/E |
| hCG P4 | N/E | |||
| Basal E2 | 0.05 mg/mL stimulated, 24 h | |||
| hCG E2 | U-shaped, 4 h, 24 h, 48 h | |||
| tyrindoleninone | GC | Basal P4 | N/E | |
| hCG P4 | N/E | |||
| Basal E2 | N-shaped, 24, 48 h | |||
| hCG E2 | N-shaped, 24, inhibition—48 h | |||
| 6-bromoisatin | GC | Basal P4 | U-shaped 4 h, N/E 24 h, 48 h | |
| hCG P4 | N/E | |||
| Basal E2 | U-shaped 4 h, N/E 24 h, 48 h | |||
| hCG E2 | Dose-dependent inhibition 4 h, 48 h | |||
| Egg mass extract 0, 0.005, 0.05, 0.5 mg/mL | mixture of 6-bromoisatin, tyrindolinone, tyrindoleninone, tyriverdin | GC | Basal P4 | N/E |
| hCG P4 | Dose-dependent stimulation, 48 h | |||
| Basal E2 | N/E | |||
| hCG E2 | Dose-dependent stimulation, 48 h | |||
| tyrindoleninone | GC | Basal P4 | N/E | |
| hCG P4 | Dose-dependent inhibition | |||
| Basal E2 | N-shaped 24, 48 h | |||
| hCG E2 | Stimulation 4, 24 h, n-shaped 48 h | |||
| Egg mass extract 0, 0.005, 0.05, 0.5 mg/mL | 6-bromoisatin | GC | Basal P4 | Lowest dose cytotoxic |
| hCG P4 | Dose-dependent inhibition, 48 h | |||
| Basal E2 | Lowest dose cytotoxic | |||
| hCG E2 | Dose-dependent stimulation, 48 h |
JAr—human chorioplacental cancer cell line, GC—human primary-derived granulosa cells, P4—progesterone, E2—estradiol 17 beta, basal—constitutive hormone synthesis, hCG—exposed to human chorionic gonadotrophin in vitro, N/E—no effect and the same as control, stimulation—steroid hormone synthesis stimulated to be significantly higher than controls, inhibition—steroid hormone synthesis significantly lower than controls, h—hours of exposure in vitro [106,136].1 N shaped curve = typical hormetic response with low dose stimulation and high dose inhibition; 2 U shaped response = inverse hormesis with low dose inhibition and high dose stimulation.
Neuromuscular and pain signalling effects of Muricidae extracts and compounds; (a) Choline ester and hypobranchial gland (HG) muscle relaxing and nicotinic activity; (b) Isatin derivative neurotransmitters, analgesics and sedative properties of the Muricidae extracts and compounds.
| M, MCH, DHM, SCH | various | Frog rectus abdominis muscle assay [ | ||||
| M, MCH | 0.75 mg/assay | Neuromuscular block in rat diaphragm assay [ | ||||
| M, MCH | 100–2000 μg/kg | % Twitch reduction assays on cat, dog and rabbit gastro-cnemius were used to calculate concentration effect [ | ||||
| M, MCH | 0.65 mg/kg | 50% rabbit head drop after i.v. injection [ | ||||
| DHM | 0.52 mg/kg | |||||
| M, MCH | 0.35 mg/kg | 50% dog paralyzing dose after i.v. injection [ | ||||
| DHM | 0.022 mg/kg | |||||
| M, MCH | 1.0–1.2 mg/kg | Relaxing effect in human preliminary clinical trial on 160 patients after a single i.v. injection [ | ||||
| M | 60 μg/kg/min (no effect) | Nicotinic effects of murexine showed a dose dependant rise in blood pressure whilst inducing neuromuscular block in anaesthetised cats and dogs [ | ||||
| M | 300 μ/kg | |||||
| 2,3 dioxoindoline | 15–20 mg/kg | Mice and rats showed anxiogenic behaviour in the open-field and elevated plus maze test and the social interaction test [ | i.p. | Monoamine oxidase B inhibition as a contribution to stress related tribulin activity. | Anxiogenic at low dose | |
| <50 mg/kg | Mice showed immobility in the forced swim test [ | i.p. | Inhibits monoamine oxidase affecting monoamine levels. | Sedative at high dose | ||
| indole-2,3-dione | 20 mg/kg | Isatin administered after pentylenetetrazole (PTZ) and 3-mercaptopropionic acid (3MPA) induced seizures in rats [ | i.p. | Antagonise natriuretic peptide receptor A (NPR-A) and NPR-C signalling at low dose due to the metabolite 5-hydroxyisatin. | Proconvulsant at low dose | |
| 60–80 mg/kg | Effective against PTZ and 3MPA induced clonic convulsions [ | i.p. | Anticonvulsant at high dose | |||
| indole-2,3-dione-3-oxime or as salt, oxide or hydrate derivative | 10 uM | Intermediate-conductance and small-conductance Ca(2+)-activated potassium channel (IKCa and SKCa)activation in a 15 ul cell chamber on human embryonic kidney 293 cell line [ | immersion | Ikca and SKca ion channel associated conditions including respiratory conditions, muscle spasms, convulsive conditions, mood disorders and dementia. | Ikca and Skca ion channel activation | |
| 5,7-dinitro-1-methyl-1H-indole-2,3-dione-3-(0-methyloxime) | 0.1–10 mg/kg | Administered to NMRI mice for ATPA rigidity, to DAB/2 mice for quisqualate seizures, to NMRI mice for | i.v. and orally (cocaine hypermotility) | Excitatory amino acid antagonist blocking glycine and glutamate on the quisqualate, 2-amino-3-(3-hydroxy-5-tert-butylisoxazol-4-yl)propionic acid (ATPA), 2-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA), kainate and NMDA receptors. | Anticonvulsant for ATPA quisqualate, NMDA seizures and cocaine hypermotility | |
| 5-bromoisatin | 200 mg/kg | Phenylquinone test for analgesia in mice showing 90% inhibition after 30 min [ | i.p. | 5-bromoisatin was comparable to acetylsalicylic and showed analgesia with fewer side effects. | Analgesic | |
| 400 mg/kg | Randall and Selitto test for analgesic comparison in rats [ | orally | ||||
| 90 mg/kg | Overall ED50 after 30 min reaction time [ | |||||
a M—murexine, was extracted from Murex trunculus, Murex brandaris and Tritonalia erinacea; MCH—murexine chloride hydrochloride (synthetic); DHM—dihydromurexine; and SCH—senecioylcholine are from hypobranchial gland extracts of the above species. Administration method includes: i.p.—intraperitoneal and i.v.—intravenous.
Toxicity of Muricidae compounds and extracts, indicating general effects (GE) and lethal dose (LD).
| Compound/Extract | Model | Test | Method Admin | Conc. (mg/kg) | General Side Effects |
|---|---|---|---|---|---|
| murexine | Mouse | LD50 | i.v. | 6.45 | Paralysis of the skeletal musculature preceded by transient stimulation including muscle tension and fasciculation. Death is caused by anoxia after peripheral respiratory arrest [ |
| LD50 | s.c. | 50 | |||
| LD (ineffective) | oral | <1000 ineffective | |||
| Dog | GE | i.v. | 0.27 | For dogs, murexine additionally caused increased saliva and evacuation of urine and faeces (defecation). Nevertheless they handled 200 times dose with artificial respiration (intubation) [ | |
| GE | s.c. | 1.35–2.16 | |||
| Pigeon | GE | i.v. | 0.05 | Birds developed contracture, leg cramp and opisthotonus instead of muscular paralysis [ | |
| LD50 | i.v. | 0.2–0.3 | |||
| Octopus | GE | i.b.h. | 30–40 | ||
| Humans | GE | i.v. | 1–1.2 | Muscle relaxation with mild nicotinic effects [ | |
| dihydromurexine | Mouse | LD50 | i.v. | 5.57 | Similar to murexine but more potent for mice. 12 times more potent for frog rectus abdominis [ |
| tigloylcholine | Mouse | LD50 | i.v. | 0.92 | Considerably more potent than murexine [ |
| Mouse | GE | oral | 0.5 | Idiosyncratic effects on hepatocytes including nonsteroidal fatty change and necrosis [ | |
| GE | oral | 0.5 | Idosyncratic gastrointestinal inflammation and ulcers [ | ||
| LD (ineffective) | oral | >1 | No mortality after 4 weeks daily oral gavage, no effects on behaviour or any signs of ill health [ | ||
| Rat | GE | oral | 1 | No mucositic, inflammation, or negative effects of gastric epithelium or blood cells [ | |
| LD (ineffective) | oral | >1 | No mortality after 1 week daily oral gavage, no effects on behaviour or any signs of ill health [ | ||
| 6-bromoisatin | Mouse | GE | oral | 0.25–1 | Diuretic effects evidenced by reduced K/Na ratio in blood no negative effects on blood cells, hemoglobin or serum liver enzymes [ |
| LD (ineffective) | oral | >1 | No mortality after 2 weeks daily oral gavage, no effects on behaviour or any signs of ill health [ |
LD50—lethal dose for 50% of group; LD (ineffective)—tested for safety with no mortality; i.v.—intravenous injection; s.c.—subcutaneous injection; i.b.h—intra branchial heart.
Ancient medicinal uses of Muricidae molluscs.
| Culture | Part of snail | Source species | Preparation | Pharmaceutical properties (Treatment) |
|---|---|---|---|---|
| Ancient Greco-Roman (Dioscorides, Oribasius and Galen) [ | Operculum | Crushed and mixed with oil and vinegar | Hearing loss, swollen spleen, depression, menstrual cycle abnormalities, after labour for placenta removal | |
| Flesh and ashes of burned shell | Burned flesh along with shell | Wound healing, cleaning teeth, treatment of cracked skin, healing parotid gland swelling, anti-inflammatory properties | ||
| Ancient Greece (Dioscorides) [ | Whole shell with meat | Muricidae ( | Burnt and dry whole animal | Cleaning teeth, healing warts, boils or tumour |
| Columellae | “Purpurae” (Muricidae) | Burnt and dry | Good for stomach | |
| Ancient Greece (Xenocrates) [ | Hypobranchial gland | unknown | Laxative, diuretic, increases salivary secretion, perspiration.Excess consumption may cause nausea, vomiting and diarrhoea | |
| Ancient Greece (Athenaeus) [ | Foot | Boiling | Heals stomach disorders | |
| Medieval Eastern Mediterranean Genizah [ | Operculum | Muricidae such as | Smell the aromatic substance or smoke produced while placing the operculum on slowly burning charcoal | Rheumatism or arthritis Stomach problem (wounds in stomach), skin diseases, teeth problems, eye and ear diseases, tumors, epilepsy , paralysis, purgative, treatment of diseases of the uterus |
| Bahrein Middle Eastern [ | Operculum | Fumigation | Atresia of uterus | |
| Europe (Aphrodisiacs) [ | Operculum
| Banded dye Murex | Operculum medicine with vinegar Fumigation | Reduced swollen spleen For women (dislodge the placenta after labour) |
| Operculum | Calcified operculum | Ashes of calcified operculum | Stimulate capillary growth |
Uses of different Muricidae family species in Traditional Chinese Medicine (TCM) 1.
| Scientific Name | Method of Use | Traditional Uses and Claims |
|---|---|---|
| Decoct the shell (10–50 g) and ingest. | Tranquilize and sedate the mind; astringe and preserve the essence; Use to treat insomnia, amnesia, spermatorrhea, uterine bleeding and leukorrhagia. | |
| Same as | Same as | |
| Decoct the shell (15–25 g) and ingest. | Resolve phlegm, disperse retention, tranquilize liver and wind; Use to treat stomach pain, scrofula and spastic muscles. | |
| Decoct the crushed shell (15–50 g); Ustulate (scorch) the shell, ground into powder and apply externally. | Clear heat, expel toxins, soften hard lumps, dispel nodes, reduce flatulence and pain; Use to treat pathopyretic ulcer, scrofula (infection of the lymph nodes), stomach pain, dyspepsia, stomach and duodenal ulcer. | |
| Decoct the shell (15–25 g) and ingest. Ustulate the shell, ground into powder and apply externally. | Clear heat, expel toxins, invigorate blood circulation. Use to treat pyretic toxicity, carbuncle, furuncle, otitis medium and ulcer of lower limb. | |
| Same as genus | Same as genus | |
| Same as | Same as | |
| Fresh meat: boil and eat the meat; decoct the shell (30–60 g) and ingest. Combine the juice and with other medicine as eye drops | Fresh meat: Remove heat to brighten vision; Use to treat hepatic heat and red eyes, ophthalmalgia, chest and abdomen heat and pain. | |
| Shell: Decoct the shell (15–30 g) and ingest, used as medicinal powder (3–6 g) and ingest; Ustulate the shell, ground into powder, mixed with sesame oil and apply externally. Operculum: Decoct the operculum (10–20 g) and ingest; Ustulate the shell, ground into powder and apply externally. | Shell: Relieve gastric hyperacidity to alleviate stomachache, resolve phlegm, disperse retention, tranquilize liver and wind; Use to treat stomach and duodenal ulcer, panasthenia, spastic hand and foot, chronic osteomyelitis, and scrofula. Operculum: Clear heat, expel toxins, remove dampness through diuresis, free strangury. Use to treat strangury (painful & frequent urination), swelling and ulcer on the body surface, hepatic coma, eye diseases, dysentery. | |
| Decoct the shell (15–25 g) and ingest. | Eliminating phlegm and soften indurated mass, relieving convulsion and spasm, relieve gastric hyperacidity to alleviate stomach ache; Use to treat stomach pain, scrofula, spastic hand and foot. | |
| same as | same as | |
| Decoct the shell (15–50 g) and ingest; used for making pills or medicinal powder; Ustulate the shell, ground into powder and apply externally. | Soften hard lumps, dispel nodes, clear heat, expel toxins; Use to treat pyogenic infection, swelling and ulcer on the body surface and scrofula. | |
| Decoct the crushed shell (15–25 g) | Soften hard lumps, dispel nodes, clear heat, expel toxins, clear expectoration, relieve cough, removing nebula to improve eyesight; Use to treat scrofula, phlegm and cough, scrofula, goitre, | |
| Same as | Same as | |
| Same as | Same as | |
| Same as | Same as | |
| Same as | Same as | |
1 The information of traditional uses are mainly retrieved from “Zhong Hua Ben Cao” or “The Chinese herbal” [23] and “Zhong Hua Hai Yang Ben Cao” [22]. Based on WoRMS, the accepted name should be 2 Murex aduncospinosus Sowerby II; 3 Murex pecten pecten Lightfoot; 4 Vokesimurex rectirostris (G.B. Sowerby II); 5 Nassa francolina (Bruguière); 6 Mancinella alouina (Röding); 7 Mancinella armigera (Link); 8 Reishia bronni (Dunker); 9 Purpura bufo (Lamarck); 10 This name is not found in WoRMS. However, it is also named as Purpura clavigera (Kuster). Based on WoRMS, the accepted name should be Reishia clavigera (Küster); 11 Mancinella echinata (Blainville); 12 Not found in WoRMS. It is also named as Purpura gradate, Purpura trigona (Reeve) and Thais trigona (Reeve). Only Purpura trigona (Reeve) was found in WoRMS. The accepted name should be Indothais gradata (Jonas); 13 Thais (Thalessa) virgata (Dillwyn); 14 Reishia luteostoma (Holten); 15 Indothais lacera (Born); 16 Menathais tuberosa (Röding).